Quick Answer
ArriVent BioPharma, Inc. reported Net Income of -$166.31 million for fiscal year 2025.
ArriVent BioPharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$166.31M | -106.6% |
| 2024 | -$80.49M | -16.1% |
| 2023 | -$69.33M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.98M | -70.1% | -11.4% |
| June 30, 2025 | -$31.40M | -43.5% | +51.2% |
| March 31, 2025 | -$64.39M | -269.7% | -213.1% |
| September 30, 2024 | -$20.56M | -42.8% | +6.0% |
| June 30, 2024 | -$21.87M | -1.4% | -25.6% |
| March 31, 2024 | -$17.42M | -43.1% | -20.9% |
| September 30, 2023 | -$14.40M | — | +33.2% |
| June 30, 2023 | -$21.57M | — | -77.2% |
- ArriVent BioPharma, Inc. showed a decrease of -106.6% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s net income has declined by 139.9% (from -$69.33 million to -$166.31 million).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: